KRAS and neoplasm: These compounds degraded the Hsp90 client HIF-1α, suppressed galectin-3, dismantled K-Ras nanoclusters, and selectively inhibited the proliferation of KRAS-mutant MIA-PaCa-2 and A549 cells (IC50 = 4–18 μM) without triggering a heat-shock response; the lead analogue FAP-967 reduced tumor volume by 62% in MIA-PaCa-2 xenografts at 50 mg kg−1.